

DAFTAR PUSTAKA

1. Petersmann A, Müller-Wieland D, Müller UA, Landgraf R, Nauck M, Freckmann G, et al. Definition, Classification and Diagnosis of Diabetes Mellitus. *Exp Clin Endocrinol Diabetes*. 2019;127:S1–7.
2. Sapra Amit B. Diabetes. *StatPearls*[Internet]. 2023.
3. Magliano DJ BE. ATLAS DIABETES IDF , edisi ke-10. ATLAS DIABETES IDF , edisi ke-10. 2021.
4. Eller-Vainicher C, Cairoli E, Grassi G, Grassi F, Catalano A, Merlotti D, et al. Pathophysiology and Management of Type 2 Diabetes Mellitus Bone Fragility. Vol. 2020, *Journal of Diabetes Research*. Hindawi Limited; 2020.
5. Paschou SA, Dede AD, Anagnostis PG, Vryonidou A, Morganstein D, Goulis DG. Type 2 diabetes and osteoporosis: A guide to optimal management. Vol. 102, *Journal of Clinical Endocrinology and Metabolism*. Oxford University Press; 2017. p. 3621–34.
6. Salari N, Ghasemi H, Mohammadi L, Behzadi M hasan, Rabieenia E, Shohaimi S, et al. The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis. Vol. 16, *Journal of Orthopaedic Surgery and Research*. BioMed Central Ltd; 2021.
7. Porter JL VMCM. Osteopenia. *StatPearls* [Internet]. 2023.
8. PUSDTIN. PUSDATIN. *InfoDATIN* [Internet]. 2020 [cited 2025 May 25];2442–7659. Available from: <https://id.scribd.com/document/511320903/Infodatin-Osteoporosis-2020>
9. Dachy JK, Khu A, Puspawani Y, Lina J, Hotma H, Marpaung H. Tingkatan Umur Terbanyak untuk Resiko Osteoporosis di Rumah Sakit Umum Royal Prima Medan Periode Tahun 2013-2016. *PRIMA Med J Artik Penelit*. 2022;7(1).
10. Zhao H, Zhen Y, Wang Z, Qi L, Li Y, Ren L, et al. The relationship between vitamin D deficiency and glycated hemoglobin levels in patients with type 2 diabetes mellitus. *Metab Syndr Obes*. 2020;13:3899–907.
11. R, Nair A. Diabetes mellitus, Vitamin D & osteoporosis: Insights. Vol. 150,



- Indian Journal of Medical Research. Wolters Kluwer Medknow Publications; 2019. p. 425–8.
12. Musazadeh V, Kavyani Z, Mirhosseini N, Dehghan P, Vajdi M. Effect of vitamin D supplementation on type 2 diabetes biomarkers: an umbrella of interventional meta-analyses. Vol. 15, Diabetology and Metabolic Syndrome. BioMed Central Ltd; 2023.
 13. Voulgaridou G, Papadopoulou SK, Detopoulou P, Tsoumana D, Giaginis C, Kondyli FS, et al. Vitamin D and Calcium in Osteoporosis, and the Role of Bone Turnover Markers: A Narrative Review of Recent Data from RCTs. Diseases. 2023 Mar 1;11(1).
 14. Kuo TR, Chen CH. Bone biomarker for the clinical assessment of osteoporosis: Recent developments and future perspectives. Vol. 5, Biomarker Research. BioMed Central Ltd.; 2017.
 15. Vasikaran S, Eastell R, Bruyère O, Foldes AJ, Garnero P, Griesmacher A, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: A need for international reference standards. Osteoporos Int. 2011 Feb;22(2):391–420.
 16. Xu G, Liu B, Sun Y, Du Y, Snetselaar LG, Hu FB, et al. Prevalence of diagnosed type 1 and type 2 diabetes among US adults in 2016 and 2017: Population based study. BMJ. 2018;362.
 17. Endokrinologi Indonesia PEDOMAN PENGELOLAAN DAN PENCEGAHAN DIABETES MELITUS TIPE P. PEDOMAN PENGELOLAAN DAN PENCEGAHAN DIABETES MELITUS TIPE 2 DEWASA DI INDONESIA-2021 PERKENI i Penerbit PB. PERKENI.
 18. Goyal R SMJI. Diabetes Tipe 2. Pulau Harta Karun, editor. Vol. NBK513253. StatPearls Publishing LLC.; 2023.
 19. Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, et al. Pathophysiology of type 2 diabetes mellitus. Vol. 21, International Journal of Sciences. MDPI AG; 2020. p. 1–34.



Jayak AK, Behera A. Type II diabetes mellitus: a review on recent drug reapeutics. Vol. 131, Biomedicine and Pharmacotherapy. Elsevier Masson).

21. Kumar, Vinay. Robbins Basic Pathology (9th Edition). 2013.
22. Narvaez J, Maldonado G, Guerrero R, Messina OD, Rios C. Vitamin d megadose: Definition, efficacy in bone metabolism, risk of falls and fractures. Vol. 12, Open Access Rheumatology: Research and Reviews. Dove Medical Press Ltd; 2020. p. 105–15.
23. Kumar V AAFNAJ. Robbins & Cotran Pathologic Basis of Disease. 10th ed. 23. Kumar V AAFNAJ, editor. English: Elsevier; 2020.
24. Chauhan K, Shahrokhi M, Huecker MR. Vitamin D. StatPearls [Internet] Treasure Isl StatPearls Publ. 2023;
25. Kaur J KSSO et al. Kekurangan Vitamin D. In: Kaur J KSSO et al, editor. StatPearls. StatPearls; 2025.
26. Jiménez-Sousa M ángeles, Martínez I, Medrano LM, Fernández-Rodríguez A, Resino S. Vitamin D in human immunodeficiency virus infection: Influence on immunity and disease. Vol. 9, Frontiers in Immunology. Frontiers Media S.A.; 2018.
27. Breeland G SMMRE. Embryology, Bone Ossification. Breeland G SMMRE, editor. Vol. 30969540. StatPearls Publishing LLC; 2023.
28. Sherwood L, Bahasa A, Brahm Pendit Editor Edisi Bahasa Indonesia dr U, Nella Yesdelita PENERBIT BUKU KEDOKTERAN mtr dr. Fisiologi Manusia Dari Sel ke Sistem (Human Physiology: From Cells fo Systems) Edisi 6. 6th ed. dr. NellaYesdelita, editor. Jakarta: Buku Kedokteran EGC; 2012.
29. Kim JM, Lin C, Stavre Z, Greenblatt MB, Shim JH. Osteoblast-Osteoclast Communication and Bone Homeostasis. Vol. 9, Cells. NLM (Medline); 2020.
30. Tobeiha M, Moghadasian MH, Amin N, Jafarnejad S. RANKL/RANK/OPG Pathway: A Mechanism Involved in Exercise-Induced Bone Remodeling. Vol. 2020, BioMed Research International. Hindawi Limited; 2020.
31. Zhang Y, Liang J, Liu P, Wang Q, Liu L, Zhao H. The RANK/RANKL/OPG system and tumor bone metastasis: Potential mechanisms and therapeutic strategies. Vol. 2022, Frontiers in Endocrinology. Frontiers Media S.A.; 2022.
32. Tadros S, Farid A, Kargilis D, Mehta S, Rajapakse CS. The Effect of Vitamin D on Bone. Vol. 11, Frontiers in Physiology. Frontiers Media S.A.; 2021.
33. Wang JD, Wan CKV, Cameron M, Austel AG, Nguyen JK, et al. Osteoporosis: A Review. Vol. 2022, Frontiers in Endocrinology. Frontiers Media S.A.; 2022.



a review of treatment options. *Pharm Ther.* 2018;43(2):92.

34. 32. Ganesan K JJAC et al. Secondary Osteoporosis. Treasure Island, editor. StatPearls; 2023.
35. Akkawi I, Zmerly H. Osteoporosis: Current concepts. Vol. 6, Joints. CIC Edizioni Internazionali s.r.l.; 2018. p. 122–7.
36. Noh JY, Yang Y, Jung H. Molecular mechanisms and emerging therapeutics for osteoporosis. Vol. 21, International Journal of Molecular Sciences. MDPI AG; 2020. p. 1–22.
37. Saxena Y, Routh S, Mukhopadhaya A. Immunoporosis: Role of Innate Immune Cells in Osteoporosis. Vol. 12, Frontiers in Immunology. Frontiers Media S.A.; 2021.
38. Sozen T, Ozisik L, Calik Basaran N. An overview and management of osteoporosis. *Eur J Rheumatol.* 2017 Mar 1;4(1):46–56.
39. Compston JE, McClung MR, Leslie WD. Osteoporosis. Vol. 393, The Lancet. Lancet Publishing Group; 2019. p. 364–76.
40. Raisz LG. Pathogenesis of osteoporosis: Concepts, conflicts, and prospects. Vol. 115, Journal of Clinical Investigation. 2005. p. 3318–25.
41. Grup RT. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. *Rec Trial Gr.* 2005 Apr 28;365:1621–8.
42. Lips P. Vitamin D Deficiency and Secondary Hyperparathyroidism in the Elderly: Consequences for Bone Loss and Fractures and Therapeutic Implications. 2001.
43. Seibel MJ. Biochemical Markers of Bone Turnover Part I: Biochemistry and Variability. 2005 Nov;26(4):97.
44. Dhaliwal R, Aloia JF. Effect of Vitamin D on Falls and Physical Performance. Vol. 46, Endocrinology and Metabolism Clinics of North America. W.B. Saunders; 2017.



Kapoor N, Bondu J, Thomas N, Paul T. Bone turnover markers: Emerging management of osteoporosis. Vol. 20, Indian Journal of Endocrinology and Metabolism. Medknow Publications; 2016. p. 846–52.

46. Kučkalić-Selimović E, Valjevac A, Hadžović-Džuvo A. The utility of procollagen type 1 N-terminal propeptide for the bone status assessment in postmenopausal women. *Bosn J basic Med Sci.* 2013;13(4):259.
47. Koivula MK, Risteli L, Risteli J. Measurement of aminoterminal propeptide of type I procollagen (PINP) in serum. Vol. 45, *Clinical Biochemistry.* 2012. p. 920–7.
48. Varela A, Jolette J. *Bone Toolbox: Biomarkers, Imaging Tools, Biomechanics, and Histomorphometry.* Vol. 46, Toxicologic Pathology. SAGE Publications Inc.; 2018. p. 511–29.
49. Fledelius C, Johnsen AH, Cloos PAC, Bonde M, Qvist P. Characterization of urinary degradation products derived from type I collagen. Identification of a β -isomerized ASP-GLY sequence within the C- terminal telopeptide (α 1) region. *J Biol Chem.* 1997 Apr 11;272(15):9755–63.
50. Garnero P, Fledelius C, Gineyts E, Serre CM, Vignot E, Delmas PD. Decreased β -isomerization of the C-terminal telopeptide of type I collagen α 1 chain in Paget's disease of bone. *J Bone Miner Res.* 1997 Sep;12(9):1407–15.
51. Hou Y, Hou X, Nie Q, Xia Q, Hu R, Yang X, et al. Association of Bone Turnover Markers with Type 2 Diabetes Mellitus and Microvascular Complications: A Matched Case-Control Study. *Diabetes, Metab Syndr Obes.* 2023;16:1177–92.
52. Konukoglu D. Bone markers. Vol. 2, *International Journal of Medical Biochemistry.* Kare Publishing; 2019. p. 65–78.
53. Han Y, You X, Xing W, Zhang Z, Zou W. Paracrine and endocrine actions of bone - The functions of secretory proteins from osteoblasts, osteocytes, and osteoclasts. Vol. 6, *Bone Research.* Sichuan University; 2018.
54. Williams C ACSA. *Biochemical Markers of Osteoporosis* [Internet]. Treasure Island (FL), editor. StatPearls; 2025 [cited 2025 Jan 25]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK559306/>
55. Fisher A, Fisher L, Srikusalanukul W, Smith PN. Bone turnover status: ion model and clinical implications. *Int J Med Sci.* 2018 Feb 1;15(4):323–



Campbell G, Napoli N, Hofbauer LC, Rauner M. Update on the impact of diabetes mellitus on bone metabolism and material properties. Vol. 8,

- Endocrine Connections. BioScientifica Ltd.; 2019. p. R55–70.
57. Krishnan A, Muthusami S. Hormonal alterations in PCOS and its influence on bone metabolism. Vol. 232, Journal of Endocrinology. BioScientifica Ltd.; 2017. p. R99–113.
 58. Wongdee K. Osteoporosis in diabetes mellitus: Possible cellular and molecular mechanisms. World J Diabetes. 2011;2(3):41.
 59. Safarova SS. Alterations of Bone Metabolism in Patients with Diabetes Mellitus. Int J Endocrinol. 2019;2019.
 60. Costantini S, Conte C. Bone health in diabetes and prediabetes. World J Diabetes. 2019 Aug 15;10(8):421–45.
 61. Murray CE, Coleman CM. Impact of diabetes mellitus on bone health. Vol. 20, International Journal of Molecular Sciences. MDPI AG; 2019.
 62. Szymczak-Pajor I, Śliwińska A. Analysis of association between vitamin d deficiency and insulin resistance. Vol. 11, Nutrients. MDPI AG; 2019.
 63. Purnamasari D, Puspitasari MD, Setiyohadi B, Nugroho P, Isbagio H. Low bone turnover in premenopausal women with type 2 diabetes mellitus as an early process of diabetes-associated bone alterations: a cross-sectional study. BMC Endocr Disord. 2017;17:1–8.
 64. Fang L, Zhong S, Ma D, Li C, Hao Y, Gao Y, et al. A cross-sectional study: an assessment of low muscle mass and osteoporosis in type 2 diabetes mellitus patients with a high glycated hemoglobin level. Ther Adv Chronic Dis. 2021;12.
 65. Suzuki A, Kotake M, Ono Y, Kato T, Oda N, Hayakawa N, et al. Hypovitaminosis D in Type 2 Diabetes Mellitus: Association with Microvascular Complications and Type of Treatment. Vol. 53, Endocrine Journal. 2006.
 66. Lahbib Ä, Ghodbane S, Maâroufi K, Louchami K, Sener A, Sakly M, et al. Vitamin D Supplementation Ameliorates Hypoinsulinemia and Hyperglycemia in Static Magnetic Field-Exposed Rat. Arch Environ Occup Heal. 2015 May 4;70(3):142–6.
 67. Sun Q, Manson JE, Dawson-Hughes B, Hu FB. Plasma 25-amin D concentration and risk of incident type 2 diabetes in women. JAMA. 2010 Sep;33(9):2021–3.
 68. Takizawa M, Tanaka M, Tetsuo T, et al. Role of vitamin



- D in energy and bone metabolism in postmenopausal women with type 2 diabetes mellitus: A 6-month follow-up evaluation. *J Diabetes Investig.* 2018 Jan 1;9(1):211–22.
69. Matsumoto T, Takano T, Saito H, Takahashi F. Vitamin D analogs and bone: preclinical and clinical studies with eldecalcitol. *Bonekey Rep.* 2014 Mar 5;3.
 70. Nagaoka H, Terajima M, Yamada S, Azuma Y, Chida T, Yamauchi M. Alfacalcidol enhances collagen quality in ovariectomized rat bones. *J Orthop Res.* 2014;32(8):1030–6.
 71. Abugoukh TM, Al Sharaby A, Elshaikh AO, Joda M, Madni A, Ahmed I, et al. Does Vitamin D Have a Role in Diabetes? *Cureus.* 2022 Oct 18;
 72. Schwetz V, Schnedl C, Urbanic-Purkart T, Trummer C, Dimai HP, Fahrleitner-Pammer A, et al. Effect of vitamin D3 on bone turnover markers in critical illness: post hoc analysis from the VITdAL-ICU study. *Osteoporos Int.* 2017 Dec 1;28(12):3347–54.
 73. Burt LA, Billington EO, Rose MS, Raymond DA, Hanley DA, Boyd SK. Effect of high-dose vitamin D supplementation on volumetric bone density and bone strength: A randomized clinical trial. *JAMA - J Am Med Assoc.* 2019 Aug 27;322(8):736–45.
 74. Olmos JM, Hernández JL, Llorca J, Nan D, Valero C, González-Macías J. Effects of 25-hydroxyvitamin D3 therapy on bone turnover markers and PTH levels in postmenopausal osteoporotic women treated with alendronate. *J Clin Endocrinol Metab.* 2012 Dec;97(12):4491–7.
 75. Bikle DD, Adams JS, Christakos S. Vitamin D: Production, Metabolism, Action, And Clinical Requirements. In: *Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism.* John Wiley & Sons; 2018. p. 230–40.
 76. D RC. Relationship between parathyroid hormone and serum creatinine levels in chronic kidney disease patients. *J Med Sci Res.* 2015 Jan 2;3(1):17–21.
- S, Yasin J, Abluwi G, Al Essa A. Vitamin D deficiency associations with bone turnover and adverse general health markers in community free ts. *BMC Endocr Disord.* 2022 Dec 1;22(1).
- A, Kekatpure AL. Postmenopausal Osteoporosis: A Literature Review.



- Cureus. 2022 Sep 20;
79. Cheng CH, Chen LR, Chen KH. Osteoporosis Due to Hormone Imbalance: An Overview of the Effects of Estrogen Deficiency and Glucocorticoid Overuse on Bone Turnover. Vol. 23, International Journal of Molecular Sciences. MDPI; 2022.
 80. Ji M, Yu Q. Primary osteoporosis in postmenopausal women. Chronic Dis Transl Med. 2015 Mar;1(1):9–13.
 81. Slopian R, Wender-Ozegowska E, Rogowicz-Frontczak A, Meczekalski B, Zozulinska-Ziolkiewicz D, Jaremek JD, et al. Menopause and diabetes: EMAS clinical guide. Maturitas. 2018 Nov 1;117:6–10.
 82. Lizcano F, Guzmán G. Estrogen deficiency and the origin of obesity during menopause. Vol. 2014, BioMed Research International. Hindawi Publishing Corporation; 2014.
 83. Mohseni M, Hosseinzadeh P, Civitelli R, Eisen S. Effect of peripheral neuropathy on bone mineral density in adults with diabetes: A systematic review of the literature and meta-analysis. Bone. 2021 Jun 1;147:115932.
 84. Riis B, Christiansen C. Actions of Thiazide on Vitamin D Metabolism: A Controlled Therapeutic Trial in Normal Women Early in the Postmenopause MATERIALS AND METHODS Participants. Vol. 34. 1985.
 85. Wang J, Li X, Li Y, Lei C. Effects of sodium-glucose cotransporter 2 inhibitors on bone metabolism in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. BMC Endocr Disord. 2024 Dec 1;24(1).
 86. Skversky AL, Kumar J, Abramowitz MK, Kaskel FJ, Melamed ML. Association of glucocorticoid use and low 25-hydroxyvitamin D levels: Results from the National Health and Nutrition Examination Survey (NHANES): 2001-2006. J Clin Endocrinol Metab. 2011 Dec;96(12):3838–45.
 87. Mita Y, Dodo K, Noguchi-Yachide T, Hashimoto Y, Ishikawa M. Structure-activity relationship of benzodiazepine derivatives as LXXLL peptide mimetics that inhibit activation of vitamin D receptor with coactivators. Bioorganic Med Chem. 2013 (4):993–1005.
 88. Caccavo NLB, Indellicati G, Celiberto F, Ierardi E, Barone M, et al. Long-Term Proton Pump Inhibitor Use on Blood Vitamins and Minerals: A



- Primary Care Setting Study. *J Clin Med*. 2023 Apr 1;12(8).
89. Widiarti W, Saputra PBT, Savitri CG, Putranto JNE, Alkaff FF. The Impact of Cardiovascular Drugs in Hyperglycemia and Diabetes: A review of 'Unspoken Side'Effect. *Hell J Cardiol*. 2024;
 90. Lange NE, Sparrow D, Vokonas P, Litonjua AA. Vitamin D deficiency, smoking, and lung function in the normative aging study. *Am J Respir Crit Care Med*. 2012 Oct 1;186(7):616–21.
 91. Tardelli VS, Lago MPP do, Silveira DX da, Fidalgo TM. Vitamin D and alcohol: A review of the current literature. Vol. 248, *Psychiatry Research*. Elsevier Ireland Ltd; 2017. p. 83–6.
 92. Vasikaran S, Thambiah SC, Tan RZ, Loh TP. The Use of Bone-Turnover Markers in Asia-Pacific Populations. Vol. 44, *Annals of Laboratory Medicine*. Korean Society for Laboratory Medicine; 2024. p. 126–34.
 93. Klein S, Gastaldelli A, Yki-Järvinen H, Scherer PE. Why does obesity cause diabetes? *Cell Metab*. 2022;34(1):11–20.
 94. WHO I. IOTF. The Asia-Pacific Perspective. Redefining Obesity and Its Treatment. *Obes Prev Manag Glob epidemic Geneva WHO*. 2000;
 95. Junita AR, Hamid F, Budu B, Natzir R, Hala Y, Alam G, et al. A potential mechanism of miana (*Coleus scutellarioides*) and quercetin via NF-κB in *Salmonella typhi* infection. *Heliyon*. 2023 Nov 1;9(11).
 96. Ridwan R, Natzir R, Rasyid H, Patellongi I, Hatta M, Linggi EB, et al. Decreased renal function induced by high-fat diet in Wistar rat: The role of plasma angiotensin converting enzyme 2 (ACE2). *Biomed Pharmacol J*. 2019;12(3):1279–87.
 97. Carnethon MR, De Chavez PJD, Biggs ML, Lewis CE, Pankow JS, Bertoni AG, et al. Association of weight status with mortality in adults with incident diabetes. *Jama*. 2012;308(6):581–90.
 98. Alloisio G, Ciaccio C, Fasciglione GF, Tarantino U, Marini S, Coletta M, et al. Effects of parathyroid hormone-related protein and other humoral osteoanabolic agents on the endogenous response of osteoblastic cells. *MDPI*; 2021.
 99. Graves DT. Diabetes and Its Effect on Bone and Fracture Healing. *Current Osteoporosis Reports*. Current Medicine Group LLC 1; 2015. p.



327–35.

100. Zafar N, Mahmood S, Anjum N, Saldera KA, Zafar S, Hafiz SA. Association between Vitamin D, P1NP, and BMD as major indicators of bone health in local population of Pakistan. *Int J Health Sci (Qassim)*. 2023 Apr 29;7(S1):271–83.
 101. Banzal N, Desai A. The impact of vitamin D3 supplementation on glycemic control in type-2 diabetes mellitus at a tertiary care hospital. *Int J Basic Clin Pharmacol*. 2020 Aug 25;9(9):1417.
 102. Abdel Aaty TA, Magallaa MH, Abdel Moneim H, Ismail HM, Genena DM, Frugina R. Serum Vitamin D Level in Type 2 Diabetic Subjects: Relation to Glycemic Control, Insulin Resistance and Proinflammatory Markers [Internet]. Vol. 47, *Journal of High Institute of Public Health*. 2017. Available from: www.jhiph.alexu.edu.eg
 103. Sinchana A, B A. A case control study of estimation of vitamin D3 levels in patients with lenticular opacity aged between 18-50 years in a tertiary institute in India. *Int J Med Ophthalmol*. 2021 Jan 1;3(1):110–2.
 104. Stewart CC, O'Hara NN, Orwig D, Hochberg MC, Sprague S, Magaziner J, et al. Serum 25(OH)D is associated with an altered bone turnover marker response after a hip fracture. *J Orthop Res*. 2019 Mar 1;37(3):535–40.
 105. Madar AA, Knutsen K V., Stene LC, Brekke M, Lagerløv P, Meyer HE, et al. Effect of vitamin D3-supplementation on bone markers (serum P1NP and CTX): A randomized, double blinded, placebo controlled trial among healthy immigrants living in Norway. *Bone Reports*. 2015 Jun 1;2:82–8.
 106. Clemens TL, Karsenty G. The osteoblast: An insulin target cell controlling glucose homeostasis. *J Bone Miner Res*. 2011 Apr;26(4):677–80.
 107. Nguyen YNH, Vong LB, Pham HA, Nguyen DQ, Phuong PNU, Mai HP, et al. The impairment of osteogenic differentiation of human adipose tissue-derived mesenchymal stem cells under high D-glucose concentrations. *Minist Sci Technol* [Internet]. 2022 Mar 15;64(1):72–7. Available from: namscience.vjst.vn/index.php/vjste/article/view/39/27
- hao H, Liu J. Vitamin D and type 2 diabetes mellitus (维生素 D 与 2 型糖尿病). 2013;5(3):261–7.



109. Manavalan JS, Cremers S, Dempster DW, Zhou H, Dworakowski E, Kode A, et al. Circulating osteogenic precursor cells in type 2 diabetes mellitus. *J Clin Endocrinol Metab.* 2012;97(9):3240–50.
110. Jorde R, Stunes AK, Kubiak J, Joakimsen R, Grimnes G, Thorsby PM, et al. Effects of vitamin D supplementation on bone turnover markers and other bone-related substances in subjects with vitamin D deficiency. *Bone.* 2019;124:7–13.
111. Tedeschi SK, Aranow C, Kamen DL, LeBoff M, Diamond B, Costenbader KH. Effect of vitamin D on serum markers of bone turnover in SLE in a randomised controlled trial. *Lupus Sci Med.* 2019;6(1).
112. Khalaf RM, Almudhi AA. The effect of vitamin D deficiency on the RANKL/OPG ratio in rats. *J Oral Biol Craniofacial Res.* 2022;12(2):228–32.
113. Kentaro Y. *Journal of Osteoporosis and Physical Bone Resorption Mechanisms Influenced by Vitamin D.* 2024;1.
114. Gunes M, Temizkan S, Apaydin T, Ilgin C, Haklar G, Yavuz DG. Serum osteoprotegerin levels, endothelial function and carotid intima-media thickness in type 2 diabetic patients. *J Diabetes Complications.* 2021;35(12):108073.
115. Yu EW, Wewalka M, Ding SA, Simonson DC, Foster K, Holst JJ, et al. Effects of gastric bypass and gastric banding on bone remodeling in obese patients with type 2 diabetes. *J Clin Endocrinol Metab.* 2016;101(2):714–22.
116. Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster J, Felsenberg D, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. *Arthritis Rheum.* 2006;54(6):1838–46.
117. Nahas-Neto J, Cangussu LM, Orsatti CL, Bueloni-Dias FN, Poloni PF, Schmitt EB, et al. Effect of isolated vitamin D supplementation on bone turnover markers in younger postmenopausal women: a randomized, double-blind, placebo-controlled trial. *Osteoporos Int.* 2018;29:1125–33.



118. Muda BC, Rosdi RAM, Zainuddin A, Isa S, Mustapaha Z. Determining optimal vitamin D level for bone health based on bone turnover markers. *Clin Lab Sci.* 2017;49(4):337–44.

119. Ferlazzo N, Costanzo MG, Caccamo D, Ientile R. Vitamin D status

- influences transcriptional levels of RANKL and inflammatory biomarkers which are associated with activation of PBMC. *Clin Chim Acta*. 2020;507:219–23.
120. Atilano-Miguel S, Barbosa-Cortés L, Ortiz-Muñiz R, Maldonado-Hernández J, Martin-Trejo JA, Rodríguez-Cruz M, et al. Changes in RANKL, OPG, and 25 (OH) D Levels in Children with Leukemia from Diagnosis to Remission. *Cancers (Basel)*. 2024;16(16):2811.
 121. Ruram AA, Chutia H, Bhattacharyya H, Handique A. Serum 25 (OH) vitamin D deficiency among young adults in the East Khasi Hills district of Meghalaya and its influence on bone mineral density: Investigating the involvement of the RANKL/RANK/OPG system. *J Fam Med Prim Care*. 2024;13(8):3042–8.
 122. Luo J, Wen H, Guo H, Cai Q, Li S, Li X. 1,25-dihydroxyvitamin D3 inhibits the RANKL pathway and impacts on the production of pathway-associated cytokines in early rheumatoid arthritis. *Biomed Res Int*. 2013;2013:1–9.
 123. Schwetz V, Trummer C, Pandis M, Grübler MR, Verheyen N, Gaksch M, et al. Effects of vitamin D supplementation on bone turnover markers: A randomized controlled trial. *Nutrients*. 2017;9(5):1–11.
 124. Saija C, Bertuccio MP, Currò M, Caccamo D. Influence of vitamin D status on the variability of collagen I C-telopeptide in pre-and post-menopausal healthy women. *J Clin Biochem Nutr*. 2025;76(3):311–6.
 125. Bao L, Wang YT, Lu MQ, Chu B, Shi L, Gao S, et al. Vitamin D deficiency linked to abnormal bone and lipid metabolism predicts high-risk multiple myeloma with poorer prognosis. *Front Endocrinol (Lausanne)*. 2023;14.
 126. Föger-Samwald U, Dovjak P, Azizi-Semrad U, Kersch-Schindl K, Pietschmann P. Osteoporosis: Pathophysiology and therapeutic options. *EXCLI J*. 2020;19:1017.
 127. Shymanskyi IO, Lisakovska OO, Veliky MM. Molecular and cellular mechanisms of vitamin D3 protection in experimental prednisolone-induced osteoporosis. *Pain Joints Spine*. 2017;7(3):93–101.



Bone Signaling & RANKL. *OrthoBullets*. 2024.

ulut SB, Yiğit P, Bayrak E, Arkan Y, Arslan F, et al. Exploring the Role of and Cytokines in Osteoporosis Development. *Biomedicines*. 2024;12(8).

, Wen R, Chang B, Cheng Y, Yi X. Role of SIRT3 in bone homeostasis

and its application in preventing and treating bone diseases. *Front Pharmacol.* 2023;14:1248507.

131. Kim BJ, Koh JM. Coupling factors involved in preserving bone balance. *Cell Mol Life Sci* [Internet]. 2019;76(7):1243–53. Available from: <https://doi.org/10.1007/s00018-018-2981-y>

